Farma

stockwalker
15.09.2020 kl 14:20 5453

Ny presentasjon lagt på web 11.09 indikerer vel hva en/ flere partnere vil kunne bli motivert av..
https://www.nordicnanovector.com/sites/default/files/presentations/NordicNanovectorSeptember%202020_updated.pdf

What’s next
• Approval of protocol amendment in multiple countries – expected October/November 2020
• Faster rate of patient enrolment starting in November 2020
• Continued implementation of initiatives to further enhance the patient recruitment rate, including a new social media strategy
• PARADIGME patient recruitment updates will be provided in each Quarterly Report

Lars virker sprekkferdig rundt dette...
• Betalutin® is an unencumbered and 100% owned asset
– Actively pursuing flexible regional commercialisation strategy to maximise value
• Efficacy observed in LYMRIT 37-01 – Part A is seen as a strength
– The response rate and mDoR in complete responders are viewed as compelling by HemOncs*
• The combination of potential benefits is what sets Betalutin® apart
– One-time treatment + durable efficacy + manageable toxicity + simplicity for patients and physicians
• HemOncs* view frail/elderly patients with co-morbidities (that prevent chemotherapy or targeted
therapies with high side-effect burden) and those refractory to RTX/anti-CD20 as Betalutin®’s ideal patients

HemOncs = Hematologists-Oncologists
Redigert 15.09.2020 kl 14:30

Rapportér innlegg

Vennligst skriv inn kommentar på hva du mener er upassende og trykk send. Dersom kommentar ikke er nødvendig, vennligst trykk send direkte.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.
E-postadressen brukes kun for å få kontakt med deg i forbindelse med advarselen.